Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 3/20 | 0.38 |
| ▸ | BTK | Q06187 | 7/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.35 |
| ▸ | MET | P08581 | 3/20 | 0.35 |
| ▸ | KDR | P35968 | 3/20 | 0.34 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ITK | Q08881 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15053835 | 0.92 | BRAF (0.37) | BRAFBTKFPR2METKDR | |
| SCHEMBL3696236 | 0.91 | BRAF (0.38) | BRAFBTKMETKDRJAK2 | |
| SCHEMBL3706712 | 0.90 | KDR (0.42) | BRAFBTKKDRFLT3 | |
| SCHEMBL3706468 | 0.90 | BTK (0.42) | BRAFBTKMETKDRJAK2 | |
| SCHEMBL3694810 | 0.89 | BRAF (0.49) | BRAFKDR | |
| SCHEMBL3698215 | 0.89 | HTR2A (0.44) | BRAFAKR1B10AKR1B1CYP1A2CYP3A4 | |
| SCHEMBL3703979 | 0.89 | STING1 (0.42) | BRAFBTKMAP3K7CYP1A2CYP3A4 | |
| SCHEMBL3709593 | 0.88 | MAP3K7 (0.40) | BRAFBTKFPR2METKDR | |
| SCHEMBL3706782 | 0.88 | KDR (0.38) | BTKMETKDRMAP3K7 | |
| SCHEMBL3695077 | 0.88 | KDR (0.39) | BRAFBTKMETKDRMAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648086-B2 | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors | ASCEPION PHARMACEUTICALS, INC. (CN) | 2014-02-11 | — | — | US | claimed |
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | JIANG, SHAN | 2012-05-17 | — | — | US | claimed |
| CN-102066372-A | 5, 6-membered heteroaryl bicyclic compounds containing a urea group as kinase inhibitors | ASCEPION PHARMACEUTICALS INC | 2011-05-18 | — | — | CN | claimed |
| US-8648086-B2 | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors | ASCEPION PHARMACEUTICALS, INC. (CN) | 2014-02-11 | — | — | US | disclosed |
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | JIANG, SHAN | 2012-05-17 | — | — | US | disclosed |
| CN-102066372-A | 5, 6-membered heteroaryl bicyclic compounds containing a urea group as kinase inhibitors | ASCEPION PHARMACEUTICALS INC | 2011-05-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | FLT3, CSF1R, EPHA2 | BRAF 114/4885BTK 38/4885FPR2 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.